FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896030903> ?p ?o ?g. }

• W2896030903 endingPage "S20" @default.
• W2896030903 startingPage "S19" @default.
• W2896030903 abstract "Anti-PD-1 therapy with nivolumab has demonstrated improved overall survival (OS) in patients with non-small-cell-lung cancer (NSCLC). Indeed, since CheckMate 017 and 057 results, nivolumab is considered as the standard of care for second line treatment of recurrent/refractory NSCLC. In the setting of advanced/metastatic NSCLC, radiation therapy, whatever its modality, is routinely used, with curative or palliative intention. Many patients receive nivolumab and radiation therapy, concomitantly or not, during the course of their disease. A synergistic effect may occur. However, data concerning this therapeutic association for NSCLC are rare. Pending the outcomes of prospective trials, we report a large series of NSCLC patients who were treated with any radiation therapy and nivolumab in order to assess toxicity and efficacy. We retrospectively reviewed records from patients of three French centers, with metastatic or refractory NSCLC irradiated, concomitantly or from six months before to three months after nivolumab. Toxicities and outcomes were analyzed. We included 103 patients (144 cranial and extra-cranial irradiated targets). An adverse event (AE) was observed in 62 (60.2%) patients and grade 3-4 AE in 10% of patients. Among them, 9 patients reported 12 grade III-IV nivolumab related side effects. Patients having received irradiation before nivolumab presented a higher risk of grade III-IV AE in comparison of with patients who received it during or after nivolumab (p = 0.001). One and 2-year OS rates were 49.3% and 29.4%, respectively whereas 1-year and 2-year PFS were 18.8% and 10.2%, respectively. Timing of irradiation delivery, before or after/during nivolumab administration was not associated to a better OS or PFS. Patients with nivolumab relative AE had statistically a better OS (p = 0.05) in comparison with patients without anti-PD1 toxicity. The combination of nivolumab with radiation therapy in patients with NSCLC was not associated with an increased risk of severe or unexpected toxicities. This study provides reassuring elements, to propose this association in clinical practice, when palliative irradiation is necessary." @default.
• W2896030903 created "2018-10-26" @default.
• W2896030903 creator A5016370905 @default.
• W2896030903 creator A5022125986 @default.
• W2896030903 creator A5032393857 @default.
• W2896030903 creator A5034083299 @default.
• W2896030903 creator A5047402540 @default.
• W2896030903 creator A5048515839 @default.
• W2896030903 creator A5049808194 @default.
• W2896030903 creator A5061601975 @default.
• W2896030903 creator A5066266071 @default.
• W2896030903 creator A5081179485 @default.
• W2896030903 date "2018-11-01" @default.
• W2896030903 modified "2023-09-30" @default.
• W2896030903 title "Clinical Outcomes of Patients with Lung Cancer Treated with Radiation Therapy Andanti-PD-1 Therapy: A Multicenter Retrospective Analysis From GFPC Group" @default.
• W2896030903 doi "https://doi.org/10.1016/j.ijrobp.2018.06.136" @default.
• W2896030903 hasPublicationYear "2018" @default.
• W2896030903 type Work @default.
• W2896030903 sameAs 2896030903 @default.
• W2896030903 citedByCount "0" @default.
• W2896030903 crossrefType "journal-article" @default.
• W2896030903 hasAuthorship W2896030903A5016370905 @default.
• W2896030903 hasAuthorship W2896030903A5022125986 @default.
• W2896030903 hasAuthorship W2896030903A5032393857 @default.
• W2896030903 hasAuthorship W2896030903A5034083299 @default.
• W2896030903 hasAuthorship W2896030903A5047402540 @default.
• W2896030903 hasAuthorship W2896030903A5048515839 @default.
• W2896030903 hasAuthorship W2896030903A5049808194 @default.
• W2896030903 hasAuthorship W2896030903A5061601975 @default.
• W2896030903 hasAuthorship W2896030903A5066266071 @default.
• W2896030903 hasAuthorship W2896030903A5081179485 @default.
• W2896030903 hasConcept C121332964 @default.
• W2896030903 hasConcept C121608353 @default.
• W2896030903 hasConcept C126322002 @default.
• W2896030903 hasConcept C141071460 @default.
• W2896030903 hasConcept C142424586 @default.
• W2896030903 hasConcept C143998085 @default.
• W2896030903 hasConcept C197934379 @default.
• W2896030903 hasConcept C2776256026 @default.
• W2896030903 hasConcept C2777701055 @default.
• W2896030903 hasConcept C2780030458 @default.
• W2896030903 hasConcept C509974204 @default.
• W2896030903 hasConcept C535046627 @default.
• W2896030903 hasConcept C71924100 @default.
• W2896030903 hasConcept C87355193 @default.
• W2896030903 hasConceptScore W2896030903C121332964 @default.
• W2896030903 hasConceptScore W2896030903C121608353 @default.
• W2896030903 hasConceptScore W2896030903C126322002 @default.
• W2896030903 hasConceptScore W2896030903C141071460 @default.
• W2896030903 hasConceptScore W2896030903C142424586 @default.
• W2896030903 hasConceptScore W2896030903C143998085 @default.
• W2896030903 hasConceptScore W2896030903C197934379 @default.
• W2896030903 hasConceptScore W2896030903C2776256026 @default.
• W2896030903 hasConceptScore W2896030903C2777701055 @default.
• W2896030903 hasConceptScore W2896030903C2780030458 @default.
• W2896030903 hasConceptScore W2896030903C509974204 @default.
• W2896030903 hasConceptScore W2896030903C535046627 @default.
• W2896030903 hasConceptScore W2896030903C71924100 @default.
• W2896030903 hasConceptScore W2896030903C87355193 @default.
• W2896030903 hasIssue "3" @default.
• W2896030903 hasLocation W28960309031 @default.
• W2896030903 hasOpenAccess W2896030903 @default.
• W2896030903 hasPrimaryLocation W28960309031 @default.
• W2896030903 hasRelatedWork W2518309888 @default.
• W2896030903 hasRelatedWork W2528057197 @default.
• W2896030903 hasRelatedWork W2544577077 @default.
• W2896030903 hasRelatedWork W2770647538 @default.
• W2896030903 hasRelatedWork W2904759734 @default.
• W2896030903 hasRelatedWork W2995534392 @default.
• W2896030903 hasRelatedWork W3097428643 @default.
• W2896030903 hasRelatedWork W4283812751 @default.
• W2896030903 hasRelatedWork W4287921968 @default.
• W2896030903 hasRelatedWork W4302292908 @default.
• W2896030903 hasVolume "102" @default.
• W2896030903 isParatext "false" @default.
• W2896030903 isRetracted "false" @default.
• W2896030903 magId "2896030903" @default.
• W2896030903 workType "article" @default.